Trince

Executive Summary

Trince Bio is a Belgian biotechnology company founded in 2019 and headquartered in Leuven. The company has developed LumiPore™, a photoporation-based cell transfection platform that enables the efficient delivery of a wide variety of payloads into cells while maintaining high cell viability. This technology addresses key limitations of traditional transfection methods, such as viral vectors and electroporation, by offering a gentle, contact-free approach suitable for both research use and the manufacturing of advanced cell therapies. Trince’s platform holds promise for enhancing the production of CAR-T cells, iPSC-derived therapies, and other cell-based treatments, where efficient and viable payload delivery is critical. As a private company at an early stage, Trince is positioned to capture value in the rapidly growing cell therapy market, which demands scalable and cost-effective manufacturing solutions. The company’s technology has the potential to become a standard tool in both academic and industrial settings, though it currently operates in a competitive landscape with other non-viral delivery platforms. Given its innovative approach and the increasing need for improved cell engineering tools, Trince is an attractive target for strategic partnerships with larger biopharma companies or CROs. The near-term focus will likely be on securing funding to advance platform validation, expand intellectual property, and engage early customers. Key risks include competition from established transfection technologies and the challenge of transitioning from research-grade to clinical-grade manufacturing. However, the company’s strong scientific foundation and clear value proposition in cell therapy manufacturing provide a solid basis for growth.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q3 2026Strategic Partnership with Cell Therapy Developer40% success
• Q4 2026Publication of Key Preclinical Data in Peer-Reviewed Journal70% success